Corcept Now Says Teva's Generic 'Materially Reduced' Korlym Pricing, While Legal Costs Join SG&A Drivers
Corcept's 10-Q turns a generic-competition warning into a stated fact and adds legal expenses to the causes of $164.4 million in quarterly SG&A.
Corcept Therapeutics, which sells the Cushing's syndrome drug Korlym and an authorized generic of it, now says in its 10-Q filed Tuesday that Teva's generic mifepristone "has materially reduced the price we receive" for those products. The same filing adds "increased legal expenses" to the reasons selling, general and administrative costs reached $164.4 million in the third quarter.
From warning to fact on pricing
The risk language has shifted from a conditional to a past-tense statement. Teva began selling its generic in January 2024, and the 10-Q says that has already cut the price Corcept gets for Korlym and its authorized generic. The prior quarter's filing said Teva's efforts "may materially harm" results if they succeeded.
The new filing also adds language that products proposed by Sun and Hikma, which have settlements allowing them to sell if the FDA approves their versions and Teva's remains available, could cut price or tablet volume further. The prior filing's dedicated discussion of the February 2026 appellate loss to Teva is gone from the risk factors.
The business is still growing. Hypercortisolism product revenue rose to $249.1 million from $207.6 million a year earlier, and higher volume accounted for 75.2 percent of that increase.
Legal bills enter the SG&A story
SG&A rose to $164.4 million from $124.0 million a year earlier, and $466.7 million for nine months versus $318.5 million. The prior filing blamed sales, marketing and pay alone; this one adds increased legal expenses. Accrued legal fees stood at $7.1 million at September 30, against $2.2 million at December 31, 2025.
Total revenue was $340.5 million, including $91.4 million from Lifyorli, the ovarian cancer drug Corcept has sold since April. Net income was $126.8 million, or $1.01 per diluted share, versus $19.7 million a year earlier, according to the earnings release. The company reiterated 2026 revenue guidance of $1.1 billion to $1.2 billion.
Cash, withholding and buybacks
Operating cash flow for the nine months was $159.7 million, up from $103.5 million. Corcept spent $55.2 million acquiring shares to cover withholding on cashless option exercises and restricted stock vesting, about ten times the $5.7 million it spent under its repurchase program. A year earlier the buyback took $172.9 million.
Cash and marketable securities stood at $662.3 million at September 30. Two decisions are due: the European Commission's final ruling on relacorilant in ovarian cancer in the fourth quarter, and the FDA's target date of December 17, 2026 on the resubmitted Cushing's application.
The FDA's December 17, 2026 target date on relacorilant for Cushing's is the next dated event.
Sources
- 10-Q Filing — Corcept Therapeutics (CORT) — SEC EDGAR
- 10-Q Filing — Corcept Therapeutics (CORT), Q2 FY2026 filed 2026-07-29 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, cort110326ex991pressrelease.htm) — Corcept Therapeutics, filed 2026-11-03 — SEC EDGAR